QT
BTAI icon

Quantbot Technologies’s BioXcel Therapeutics BTAI Stock Holding History

Quantbot Technologies’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-131
Closed -$5.31K – 1595
2023
Q3 		$5.31K Buy
+131
New +$13.2K ﹤0.01% 1448
2022
Q4 		– Sell
-305
Closed -$57K – 1699
2022
Q3 		$57K Buy
+305
New +$70.8K ﹤0.01% 1218
2022
Q2 		– Sell
-239
Closed -$79K – 1724
2022
Q1 		$79K Buy
+239
New +$69.3K 0.01% 1094
2021
Q1 		– Sell
-19
Closed -$13K – 1427
2020
Q4 		$13K Sell
19
-25
-57% -$19.5K ﹤0.01% 1068
2020
Q3 		$30K Buy
+44
New +$33K ﹤0.01% 948

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quantbot Technologies's BTAI Position: Q4 2023 in Review

Quantbot Technologies sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 131 shares — an estimated $5.31K sold.

Quantbot Technologies first reported a position in BTAI in Q3 2020 and held it in 5 quarters. The position peaked at $79K in Q1 2022. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Quantbot Technologies reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Quantbot Technologies sold 131 BioXcel Therapeutics shares in Q4 2023, an estimated $5.31K.
  • Quantbot Technologies first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 5 quarters.
  • Quantbot Technologies's BioXcel Therapeutics position peaked at $79K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Quantbot Technologies's 13F filing for Q4 2023, filed 14 Feb 2024.